Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Is The Systemic Aspergillosis And Systemic Candidiasis Market Expected To Grow In Terms Of Size?
The market size for systemic aspergillosis and systemic candidiasis has been on a steady upward trajectory in the past few years. The market, which is projected to escalate from $7.24 billion in 2024 to $7.57 billion in 2025, is expected to experience a compound annual growth rate (CAGR) of 4.5%. Factors contributing to growth during the historical period include a rise in the number of fungal infections, an increase in the immunocompromised patient population, advancements in diagnostic technologies, the prevalence of invasive medical procedures, and global proliferation of infections.
Anticipations run high for a sturdy expansion of the systemic aspergillosis and systemic candidiasis market in the upcoming years, with expectations pointing to a size of $9.24 billion by 2029, symbolizing a compound annual growth rate (CAGR) of 5.1%. The predicted growth trajectory in the forecast timeframe can be linked to factors such as global antifungal resistance monitoring, an increasing aging population, the advent of telemedicine allowing remote medical consultations, development of drugs focused on the patient, and digital healthcare methods for patient management. Looking ahead, key developments to watch during the forecast period include the discovery of new fungal biomarkers for early diagnosis, the introduction of unique antifungal drugs, progress in immunotherapy, and the development of cutting-edge drug delivery systems.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12148&type=smp
Which Key Factors Are Fueling Growth In The Systemic Aspergillosis And Systemic Candidiasis Market?
The rise in the occurrence of fungal diseases is predicted to spur the growth of the systemic aspergillosis and systemic candidiasis market in the future. Infections resulting from fungi, referred to as fungal diseases, can impact different body parts, leading to a range of symptoms and complications. These diseases encompass cutaneous skin infections, respiratory infections, and systemic infections. Treatments for fungal diseases include antifungal medications like oral azoles, voriconazole, and liposomal amphotericin B. For example, the Lancet, a London-based medical journal and globally recognized health knowledge source, reported in July 2024 that there are roughly 6.5 million cases of invasive fungal infections each year, leading to 3.8 million deaths. About 2.5 million of these deaths are directly tied to the infections. Therefore, the escalation in fungal disease occurrence is driving the systemic aspergillosis and systemic candidiasis market’s expansion.
How Is The Systemic Aspergillosis And Systemic Candidiasis Market Categorized Across Applications And Types?
The systemic aspergillosis and systemic candidiasismarket covered in this report is segmented –
1) By Type: Systemic Oral Azoles; Voriconazole; Liposomal Amphotericin B; Topical Antifungal Agents; Other Types
2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA); Chronic Pulmonary Aspergillosis (CPA); Gastrointestinal Candidiasis; Genitourinary Tract Candidiasis; Other Applications
3) By End User: Clinic; Hospital; Other End Users
Subsegments:
1) By Systemic Oral Azoles: Fluconazole; Itraconazole; Posaconazole; Voriconazole
2) By Voriconazole: Voriconazole Tablets; Voriconazole Injection
3) By Liposomal Amphotericin B: Liposomal Amphotericin B For Systemic Aspergillosis; Liposomal Amphotericin B For Systemic Candidiasis
4) By Topical Antifungal Agents: Topical Azoles; Topical Polyenes; Topical Allylamines
5) By Other Types: Echinocandins; Antifungal Combination Therapies; Other Emerging Antifungal Agents
Which Emerging Trends Are Reshaping The Systemic Aspergillosis And Systemic Candidiasis Market Landscape?
Key players in the systemic aspergillosis and systemic candidiasis markets are focusing their efforts on developing innovative products, including echinocandins, to improve treatment effectiveness and counter rising antifungal resistance issues. Echinocandins are a type of antifungal medication that restricts the creation of ß-glucan, a crucial fungal cell wall component. For example, in March 2023, both Cidara Therapeutics and Melinta Therapeutics, biotechnology firms based in the US, obtained approval from the Food and Drug Administration (FDA), a US federal public health protection agency, for REZZAYO (rezafungin for injection). This novel echinocandin, administered once weekly, is intended for the treatment of candidemia in adults when other treatment options are limited or not available. Its user-friendly administration and once-weekly dosage schedule make REZZAYO a significant contribution to the continuity of care for patients suffering from invasive candidiasis, especially within hospital environments where effective infection control is paramount.
Which Firms Are Making The Biggest Impact In The Systemic Aspergillosis And Systemic Candidiasis Market?
Major companies operating in the systemic aspergillosis and systemic candidiasis market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline PLC, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Matinas BioPharma Holdings Inc., Shionogi & Co. Ltd, Cipla Limited, Taj Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Cidara Therapeutics Inc., T2 Biosystems Inc., Sandoz International GmbH, Grupo Ferrer International S.A., Entasis Therapeutics Inc., F2G Ltd., Mycovia Pharmaceuticals Inc., ContraFect Corporation, Enzon Pharmaceutical Inc., Pacgen Life Science Corporation, Biosergen AS, N8 Medical LLC
Access The Complete Report Here:
Which Region Holds The Greatest Opportunity For Systemic Aspergillosis And Systemic Candidiasis Market Expansion?
North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=12148&type=smp
Browse Through More Reports Similar to the Global Systemic Aspergillosis And Systemic Candidiasis Market 2025, By The Business Research Company
Motor Vehicle And Parts Dealers Global Market Report 2025
Automobiles And Heavy Equipment Global Market Report 2025
Electric Motor And Generator Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/electric-motor-and-generator-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model